Evaluation of [18F] PBR06 and Positron Emission Tomography (PET) as a Marker of Inflammation in Subjects With Neurological Conditions
Summary
The underlying goal of this study is to assess [18F] PBR06 PET imaging as a tool to detect microglial activation in the brain of Alzheimer Disease (AD), Parkinson Disease (PD) and Multiple Sclerosis (MS) research participants.
Study Design
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Conditions
Alzheimer Disease
Intervention
[18F] PBR06
Location
Institute for Neurodegenerative Disorders
New Haven
Connecticut
United States
06510
Status
Recruiting
Source
Institute for Neurodegenerative Disorders
Results (where available)
Links
- Source: http://clinicaltrials.gov/show/NCT01028209
- Information obtained from ClinicalTrials.gov on July 15, 2010
Published on BioPortfolio: 2014-08-27T03:17:25-0400
Clinical Trials
Evaluating an innovative molecular imaging technique to visualize inflammation of the atherosclerotic plaque in patients with a recent ischemic stroke ( 50%, by performing a Positron emission to...
Dominantly Inherited Alzheimer Network (DIAN)
The purpose of this study is to identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.
Blood Biomarker of Alzheimer's Disease (AD)
Currently, no cures or disease modifying therapies exist for Alzheimer's disease (AD). This is partially due to the inability to detect the disease before it has progressed to a stage wher...
Biodistribution of [11C]PIB in Patients With Risk Factors for Alzheimer's Disease
Participants enrolled in the Alzheimer's Disease Clinical Core at Wake Forest School of Medicine will be invited to take part in this study. The purpose of this study is to identify and me...
Effect of Choline Alphoscerate on Cognitive Function in Alzheimer's Dementia
This study will evaluate the performance of Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) in patients with Alzheimer's disease (AD).
PubMed Articles
Neuroimaging modalities can measure different aspects of the disease process in Alzheimer's disease, although the relationship between these modalities is unclear.
Chronic neuroinflammation has been implicated in Alzheimer's disease (AD) pathology.
Exploring the role of Alzheimer's disease (AD) implicated pathways in the predementia phase may provide new insight for preventive and clinical trials targeting disease specific pathways.
Cortical microstructural changes along the Alzheimer's disease continuum.
Cortical mean diffusivity (MD) and free water (FW) changes are proposed biomarkers for Alzheimer's disease (AD).
Memantine for Alzheimer's Disease: An Updated Systematic Review and Meta-analysis.
The clinical benefit of memantine for Alzheimer's disease (AD) remains inconclusive.
Medical and Biotech [MESH] Definitions
Neuropil Threads
Abnormal structures located chiefly in distal dendrites and, along with NEUROFIBRILLARY TANGLES and SENILE PLAQUES, constitute the three morphological hallmarks of ALZHEIMER DISEASE. Neuropil threads are made up of straight and paired helical filaments which consist of abnormally phosphorylated microtubule-associated tau proteins. It has been suggested that the threads have a major role in the cognitive impairment seen in Alzheimer disease.
Alzheimer Vaccines
Vaccines or candidate vaccines used to prevent or treat ALZHEIMER DISEASE.
Aphasia, Primary Progressive
A progressive form of dementia characterized by the global loss of language abilities and initial preservation of other cognitive functions. Fluent and nonfluent subtypes have been described. Eventually a pattern of global cognitive dysfunction, similar to ALZHEIMER DISEASE, emerges. Pathologically, there are no Alzheimer or PICK DISEASE like changes, however, spongiform changes of cortical layers II and III are present in the TEMPORAL LOBE and FRONTAL LOBE. (From Brain 1998 Jan;121(Pt 1):115-26)
Rivastigmine
A carbamate-derived reversible CHOLINESTERASE INHIBITOR that is selective for the CENTRAL NERVOUS SYSTEM and is used for the treatment of DEMENTIA in ALZHEIMER DISEASE and PARKINSON DISEASE.
Protein Aggregation, Pathological
A biochemical phenomenon in which misfolded proteins aggregate either intra- or extracellularly. Triggered by factors such as MUTATION, POST-TRANSLATIONAL MODIFICATIONS, and environmental stress, it is generally associated with ALZHEIMER DISEASE; PARKINSON DISEASE; HUNTINGTON DISEASE; and TYPE 2 DIABETES MELLITUS.
